Literature DB >> 12794754

Expression profiles of angiogenic growth factors in squamous cell carcinomas of the head and neck.

Simon Ninck1, Christoph Reisser, Gerhard Dyckhoff, Burkhard Helmke, Harald Bauer, Christel Herold-Mende.   

Abstract

Inhibition of angiogenesis by blocking angiogenic cytokines or their pathways has become a major target in experimental cancer therapies. This therapeutical approach requires a profound knowledge of growth factor profiles that contribute to tumor growth and progression. The respective knowledge is presently rather incomplete for head and neck squamous cell carcinomas (HNSCC). Therefore we studied expression of several angiogenic cytokines including VEGF, bFGF, PDGF-AB, PDGF-BB, G-CSF and GM-CSF in HNSCC in vivo and in vitro. In tumor tissues expression of all cytokines was observed albeit with marked differences concerning intensity and distribution pattern. Quantification of the cytokines in the supernatant of 15 tissue-corresponding HNSCC cultures revealed that VEGF, PDGF-AB and less frequently GM-CSF were secreted in high amounts of up to 13 ng/ml/10(6) cells. Twenty percent of the HNSCC cultures expressed only 1 cytokine in biologically active amounts, 60% 2 or 3 and 20% expressed the maximum of 4 cytokines simultaneously. Interestingly, we observed a distinct cytokine pattern: HNSCC cells secreting only 1 or 2 cytokines presented always with either VEGF and/or PDGF-AB, while G-CSF and GM-CSF were secreted primarily together with VEGF and PDGF-AB. The number of cytokines expressed by HNSCC cells correlated with the microvessel density of the original tumor and with the clinical outcome: tumors producing at least 3 cytokines revealed a significantly poorer patient prognosis. Our data indicate a major role for VEGF and PDGF-AB in HNSCC and that the additional secretion of G-CSF or GM-CSF might contribute to a poorer prognosis in patients suffering from these tumors. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12794754     DOI: 10.1002/ijc.11188

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  31 in total

Review 1.  Phenotypic and functional plasticity of cells of innate immunity: macrophages, mast cells and neutrophils.

Authors:  Stephen J Galli; Niels Borregaard; Thomas A Wynn
Journal:  Nat Immunol       Date:  2011-10-19       Impact factor: 25.606

2.  Loss of SOX2 expression induces cell motility via vimentin up-regulation and is an unfavorable risk factor for survival of head and neck squamous cell carcinoma.

Authors:  Pilar Bayo; Adriana Jou; Albrecht Stenzinger; Chunxuan Shao; Madeleine Gross; Alexandra Jensen; Niels Grabe; Christel Herold Mende; Pantelis Varvaki Rados; Juergen Debus; Wilko Weichert; Peter K Plinkert; Peter Lichter; Kolja Freier; Jochen Hess
Journal:  Mol Oncol       Date:  2015-05-20       Impact factor: 6.603

3.  Antiproliferative efficacies but minor drug transporter inducing effects of paclitaxel, cisplatin, or 5-fluorouracil in a murine xenograft model for head and neck squamous cell carcinoma.

Authors:  Dirk Theile; Zoltan Gal; Rolf Warta; Juan Pablo Rigalli; Bernd Lahrmann; Niels Grabe; Christel Herold-Mende; Gerhard Dyckhoff; Johanna Weiss
Journal:  Cancer Biol Ther       Date:  2014-01-21       Impact factor: 4.742

Review 4.  Off-tumor target--beneficial site for antiangiogenic cancer therapy?

Authors:  Yihai Cao
Journal:  Nat Rev Clin Oncol       Date:  2010-08-03       Impact factor: 66.675

5.  A peptide derivative serves as a fibroblast growth factor 2 antagonist in human gastric cancer.

Authors:  Lei Fan; Wulan Li; Shilong Ying; Lingyi Shi; Zhe Wang; Gaozhi Chen; Hui Ye; Xiaoping Wu; Jianzhang Wu; Guang Liang; Xiaokun Li
Journal:  Tumour Biol       Date:  2015-04-19

6.  Inactivation of the putative suppressor gene DOK1 by promoter hypermethylation in primary human cancers.

Authors:  Amandine Saulnier; Thomas Vaissière; Jiping Yue; Maha Siouda; Marine Malfroy; Rosita Accardi; Marion Creveaux; Sinto Sebastian; Naveed Shahzad; Tarik Gheit; Ishraq Hussain; Mariela Torrente; Fausto Antonio Maffini; Luca Calabrese; Fausto Chiesa; Cyrille Cuenin; Ruchi Shukla; Ikbal Fathallah; Elena Matos; Alexander Daudt; Sergio Koifman; Victor Wünsch-Filho; Ana M B Menezes; Maria-Paula Curado; David Zaridze; Paolo Boffetta; Paul Brennan; Massimo Tommasino; Zdenko Herceg; Bakary S Sylla
Journal:  Int J Cancer       Date:  2011-09-22       Impact factor: 7.396

Review 7.  Harnessing cancer immunotherapy during the unexploited immediate perioperative period.

Authors:  Pini Matzner; Elad Sandbank; Elad Neeman; Oded Zmora; Vijaya Gottumukkala; Shamgar Ben-Eliyahu
Journal:  Nat Rev Clin Oncol       Date:  2020-02-17       Impact factor: 66.675

8.  Angiogenic heterogeneity in head and neck squamous cell carcinoma: biological and therapeutic implications.

Authors:  Rifat Hasina; Mark E Whipple; Leslie E Martin; Winston Patrick Kuo; Lucila Ohno-Machado; Mark W Lingen
Journal:  Lab Invest       Date:  2008-02-18       Impact factor: 5.662

9.  G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models.

Authors:  Farbod Shojaei; Xiumin Wu; Xueping Qu; Marcin Kowanetz; Lanlan Yu; Martha Tan; Y Gloria Meng; Napoleone Ferrara
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-03       Impact factor: 11.205

10.  The Multifaceted Roles Neutrophils Play in the Tumor Microenvironment.

Authors:  Ronit Vogt Sionov; Zvi G Fridlender; Zvi Granot
Journal:  Cancer Microenviron       Date:  2014-06-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.